Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,746,638
  • Shares Outstanding, K 57,117
  • Annual Sales, $ 36,560 K
  • Annual Income, $ -88,980 K
  • EBIT $ 27 M
  • EBITDA $ 28 M
  • 60-Month Beta 1.10
  • Price/Sales 8.97
  • Price/Cash Flow N/A
  • Price/Book 5.23

Options Overview Details

View History
  • Implied Volatility 90.92% (-0.80%)
  • Historical Volatility 70.98%
  • IV Percentile 26%
  • IV Rank 20.74%
  • IV High 216.89% on 03/10/25
  • IV Low 57.95% on 05/20/25
  • Expected Move (DTE 1) 1.87 (6.04%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 75
  • Volume Avg (30-Day) 262
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 8,928
  • Open Int (30-Day) 8,754
  • Expected Range 29.10 to 32.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.75
  • Number of Estimates 4
  • High Estimate -0.57
  • Low Estimate -0.84
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -316.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.21 +22.85%
on 01/12/26
37.34 -17.06%
on 01/07/26
-1.42 (-4.38%)
since 12/12/25
3-Month
20.32 +52.41%
on 11/05/25
38.69 -19.96%
on 10/16/25
-3.97 (-11.36%)
since 10/14/25
52-Week
5.35 +478.88%
on 04/09/25
38.69 -19.96%
on 10/16/25
+22.29 (+256.80%)
since 01/14/25

Most Recent Stories

More News
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA submission planned to initiate in first half 2027— ...

STOK : 30.97 (+1.28%)
BIIB : 169.31 (-5.04%)
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.97 (+1.28%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.97 (+1.28%)
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free...

STOK : 30.97 (+1.28%)
BIIB : 169.31 (-5.04%)
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free...

STOK : 30.97 (+1.28%)
BIIB : 169.31 (-5.04%)
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

– New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential...

STOK : 30.97 (+1.28%)
BIIB : 169.31 (-5.04%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.97 (+1.28%)
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative...

STOK : 30.97 (+1.28%)
BIIB : 169.31 (-5.04%)
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative...

STOK : 30.97 (+1.28%)
BIIB : 169.31 (-5.04%)
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.97 (+1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

3rd Resistance Point 32.44
2nd Resistance Point 31.79
1st Resistance Point 31.38
Last Price 30.97
1st Support Level 30.32
2nd Support Level 29.67
3rd Support Level 29.26

See More

52-Week High 38.69
Last Price 30.97
Fibonacci 61.8% 25.96
Fibonacci 50% 22.02
Fibonacci 38.2% 18.09
52-Week Low 5.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar